Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

✍ Scribed by Kreitman, R. J.; Tallman, M. S.; Robak, T.; Coutre, S.; Wilson, W. H.; Stetler-Stevenson, M.; FitzGerald, D. J.; Lechleider, R.; Pastan, I.

• Book ID: 115468982
• Publisher: American Society of Clinical Oncology
• Year: 2012
• Tongue: English
• Weight: 184 KB
• Volume: 30
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/jco.2011.38.1756